Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

431.34 +1.88 (+0.44%)
Streaming Delayed Price Updated: 10:34 AM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Large-Cap U.S. Equities Showing Narrow Breadth In Year-To-Date Performance
Via Talk Markets
2 Newly Minted AI Stocks to Buy Right Now
Eli Lilly and Medtronic have recently joined the burgeoning field of AI stocks. 
Via The Motley Fool
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
Nvidia Becomes Ninth Company To Hit $1 Trillion Market Cap — Who Could Be Next To Join Elusive Club?
A surge in price for shares of Nvidia Corporation (NASDAQ: NVDA) after the company’s quarterly earnings results and guidance has put the semiconductor company in the elusive $1 trillion market... 
Via Benzinga
Eli Lilly Unusual Options Activity For May 30
 
Via Benzinga
Better Dividend Stock: Eli Lilly or Novo Nordisk?
One of these dividend-paying pharma stocks is a markedly better passive income vehicle. 
Via The Motley Fool
This Pharma's Sales Are So Hot It's Trying to Curb Demand
Wegovy's nearly guaranteed to make Novo Nordisk billions of dollars. 
Via The Motley Fool
7 Overvalued Value Stocks to Sell Before June 2023
Eventually, even heavily discounted enterprises lose their charm, transitioning to become overvalued value stocks to sell. 
Via InvestorPlace
3 High-Growth Stocks to Buy Before They Join the Trillion-Dollar Club
The next trillion-dollar companies will join an elite club comprised of a handful of the most valuable firms globally. 
Via InvestorPlace
Hagens Berman: Settlement Worth in Excess of $500 Million Reached in Insulin Pricing Class-Action Lawsuit
From Hagens Berman
Via Business Wire
$100 Invested In This Stock 20 Years Ago Would Be Worth $700 Today
 
Via Benzinga
Can Pfizer Stock Double Your Money in 3 Years?
Wall Street may be overlooking the potential of the drugmaker's GLP-1 pipeline assets. 
Via The Motley Fool
Eli Lilly Unusual Options Activity For May 23
 
Via Benzinga
Eli Lilly and Company (NYSE: LLY) Climbs to New 52-Week High
Via Investor Brand Network
Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected
Like Pfizer and Novo Nordisk, Eli Lilly is also testing an oral GLP-1 in weight loss. 
Via Investor's Business Daily
3 Biotech Stocks Sitting on Huge-Upside Catalysts
The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks. 
Via InvestorPlace
7 Top Stock Tips for June 2023
The stock market remains unpredictable and volatile. As such, investors should be aware of the following top stock tips for the second half. 
Via InvestorPlace
Zura Bio's Veteran Leadership Eyes Repeat Success, Confident Analyst Sees 150% Upside
 
Via Benzinga
As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction
(Wednesday market open) Investors seeking distraction from the ticking debt ceiling countdown clock get some this afternoon in the form of Federal Reserve meeting minutes and Nvidia (NASDAQ: NVDA)... 
Via Benzinga
Looking At Eli Lilly's Recent Unusual Options Activity
 
Via Benzinga
Ranked: Who Made The Most U.S. Unicorn Acquisitions Since 1997?
Unicorn acquisitions are driven by two factors: the rate at which new unicorns are minted, and the climate for M&A transactions more broadly. 
Via Talk Markets
7 Stocks That Could Be the Next $2 Trillion-Dollar Companies
AI, the cloud transition and success in the pharmaceutical sector will help these firms become future $2 trillion companies. 
Via InvestorPlace
The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes
Pfizer stock surged on its diabetes news this week, but one analyst says there's a key piece missing from the story. 
Via Investor's Business Daily
Microsoft To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
Credit Suisse cut the price target for Big Lots, Inc. (NYSE: BIG) from $13 to $7. Credit Suisse analyst Karen Short maintained an Underperform rating. Big Lots shares gained 2.9% to $8.15 in pre-market... 
Via Benzinga
Pfizer Stock Pops: Study Shows Company's Oral Weight Loss Drug Could Be As Effective As Novo Nordic's Ozempic Injection
Pfizer Inc (NYSE: PFE) shares are trading higher Monday in the wake of a newly released study suggesting the company's oral weight loss drug may be as effective as Novo Nordisk's (NYSE: NVO)  
Via Benzinga
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Pfizer's diabetes drug led to faster weight loss than Novo Nordisk's Ozempic. 
Via Investor's Business Daily
Lifestyle Drugs Market to Eyewitness Massive Growth : Eli Lilly, Pfizer, BMS, AstraZeneca
Stay up-to-date with Lifestyle Drugs Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Exposures Product Safety
The 3 Best Momentum Stocks to Buy in May 2023
These momentum stocks have certainly picked up the pace in recent months, and I think this could continue in May and beyond. 
Via InvestorPlace
Here's Why I Still Own Alexandria Real Estate Equities
This office owner is not like the rest, which could be a very good thing. 
Via The Motley Fool
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.